Acquisition of Surmodics by GTCR Expected to Close Promptly

November 17, 2025—Surmodics, Inc. announced that it expects to close promptly the previously announced acquisition (“merger”) of the company by an affiliate of GTCR LLC.

In May 2024, the company announced that it entered into a definitive agreement to be acquired by GTCR, a private equity firm with expertise across health care and health care technology.

The company advised that the Federal Trade Commission and certain state regulators (the plaintiffs) filed a joint status report with the United States District Court for the Northern District of Illinois stating that they do not intend to appeal the November 10 ruling by the District Court denying the plaintiffs’ motion for a preliminary injunction to prevent the closing of the merger.

According to the company, consummation of the merger is subject to the satisfaction or waiver of closing conditions set forth in the merger agreement, including the absence of any injunction or other legal restraint or prohibition that would prevent or prohibit the consummation of the merger; the absence of a material adverse effect with respect to the company; and other customary closing conditions.